Gathering evidence about the impact of COVID-19 on autoimmune liver disease patients
COVID-19 - Risks for Patients
Because autoimmune liver diseases are rare, gathering evidence about the impact of COVID-19 is difficult. The ERN RARE-LIVER would like to ask autoimmune liver disease patients a few questions about how they are affected. The results will be used to build a more robust evidence base about the risks of coronavirus to autoimmune liver disease patients.
Please Take the Survey
Please can you spare a few minutes to complete this survey? It's available in English, Dutch, German, Swedish (French, Italian, Portuguese, Spanish and Polish coming soon) - click on the right hand side to access different languages.
What is the ERN RARE-LIVER?
ERN RARE-LIVER is a Europe-wide network for centres of excellence in the clinical management of rare liver disease in adults and in children. PSC Support sits on the Management Board for the network. The goal of the ERN is to raise standards in care and advance rare liver disease research across Europe.